Dapivirine vs Emtricitabine (Emtriva)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: HIV reverse transcriptase · full HIV pipeline

Dapivirine · Dapivirine Vaginal Ring

Marketed by Population Council and partners

Phase 3 in HIVsmall molecule
Reliable signal

NCT01617096 · Phase 3 · completed

This Phase 3 trial randomized 2,629 women to a monthly dapivirine vaginal ring or a placebo ring, with participants and investigators blinded, and used HIV-1 seroconversion as the primary endpoint. The published analysis shows a 27% lower incidence of HIV-1 infection with dapivirine (95% CI 1 to 46; P = 0.046). The design is robust and the primary comparison is statistically significant, although the effect was smaller where adherence was low.

Reported efficacy

Efficacy as Determined by the Proportion of Women in Each Arm With HIV-1 Seroconversion After 120 Endpoints Are Observed in the Trial. (minimum of 12 months and a maximum of 14 months per participant); The Number of Participants That Experienced Grade 2, 3, 4 and Serious Adverse Events Over the Investigational Product Used Period (25 mg Dapivirine Administered in a Silicone Elastomer Vaginal Matrix Ring (DVR), Inserted Once Every 4 Weeks). (minimum of 12 months and a maximum of 14 months per participant): HIV-1 seroconversion: 71/1313 dapivirine vs 97/1313 placebo; incidence 27% lower with dapivirine (95% CI 1 to 46; P = 0.046), 37% lower after exclusion of two low-adherence sites (P = 0.007). (met)

Result source: NCT01617096

Emtricitabine (Emtriva)

Marketed by Gilead Sciences and partners

Approved in HIVsmall molecule
Partial signal

NCT00112047 · Phase 3 · completed

The trial randomized 517 participants to an active comparator, but treatment was open-label rather than double-blinded. Its hard clinical virologic endpoint was met: 84.4% versus 72.8% achieved confirmed HIV-1 RNA below 400 copies/mL at week 48 (p=0.002; 95% CI for the difference, 4.3% to 18.6%), supporting non-inferiority and a favorable result, but the lack of blinding limits the evidence strength.

Next expected readout: June 2029 · NCT07792096 (registry estimate)

Reported efficacy

Percentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 48 (Defined by the Food and Drug Administration [FDA] Time-to-Loss-of Virologic Response [TLOVR] Algorithm (48 weeks): Percentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 48 (Defined by the Food and Drug Administration [FDA] Time-to-Loss-of Virologic Response [TLOVR] Algorithm (48 weeks): EFV+FTC+TDF 84.4 Percentage of participants | CBV+EFV 72.8 Percentage of participants (met)

Result source: NCT00112047

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDapivirineEmtricitabine (Emtriva)
HIV-1 RNA below 50 copies/mL (week 48)—Trial running · NCT06250504—Not posted · NCT00002416
HIV-1 RNA 50 copies/mL or more (week 48)—Trial running · NCT06250504—Not posted · NCT00002416
CD4 count, change (week 48)—Trial running · NCT06250504—Not posted · NCT00002416

HIV-1 RNA below 50 copies/mL (week 48)

Dapivirine
—Trial running · NCT06250504
Emtricitabine (Emtriva)
—Not posted · NCT00002416

HIV-1 RNA 50 copies/mL or more (week 48)

Dapivirine
—Trial running · NCT06250504
Emtricitabine (Emtriva)
—Not posted · NCT00002416

CD4 count, change (week 48)

Dapivirine
—Trial running · NCT06250504
Emtricitabine (Emtriva)
—Not posted · NCT00002416
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Emtricitabine (Emtriva)
Percentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 48 (Defined by the Food and Drug Administration [FDA] Time-to-Loss-of Virologic Response [TLOVR] Algorithm (48 weeks): EFV+FTC+TDF 84.4 Percentage of participants | CBV+EFV 72.8 Percentage of participants NCT00112047 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Dapivirine: 4 of 4 rows · Emtricitabine (Emtriva): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricDapivirine
Dropout rate
11.3%25 mg DVR inserted once every 4 weeksa
NCT01617096 · Phase 3 · monotherapy
show 9 more results
9.9%25 mg
NCT02862171 · Phase 3
3.6%25 mg vaginal matrix ring
NCT02858037 · Phase 3 · registry result, not featured evidence
—
NCT03593655 · Phase 2 · registry result, not featured evidence
5.5%
NCT02028338 · Phase 2 · registry result, not featured evidence
2.8%
NCT02010593 · Phase 2 · registry result, not featured evidence
20.9%Dapivirine Gel 4759
NCT00799058 · Phase 1/2 · registry result, not featured evidence
23.3%Dapivirine Gel 4789
NCT00799058 · Phase 1/2 · registry result, not featured evidence
10.5%
NCT03239483 · Phase 1 · registry result, not featured evidence
31%
NCT01539226 · Phase na · registry result, not featured evidence
Discontinued due to AEs
—25 mg DVR inserted once every 4 weeksa
NCT01617096 · Phase 3 · monotherapy
show 9 more results
—25 mg
NCT02862171 · Phase 3
—25 mg vaginal matrix ring
NCT02858037 · Phase 3 · registry result, not featured evidence
—
NCT03593655 · Phase 2 · registry result, not featured evidence
—
NCT02028338 · Phase 2 · registry result, not featured evidence
—
NCT02010593 · Phase 2 · registry result, not featured evidence
4.7%Dapivirine Gel 4759
NCT00799058 · Phase 1/2 · registry result, not featured evidence
0%Dapivirine Gel 4789
NCT00799058 · Phase 1/2 · registry result, not featured evidence
—
NCT03239483 · Phase 1 · registry result, not featured evidence
0%
NCT01539226 · Phase na · registry result, not featured evidence
Serious AEs
8.8%25 mg DVR inserted once every 4 weeksa
NCT01617096 · Phase 3 · monotherapy
show 9 more results
2.1%25 mg
NCT02862171 · Phase 3
1.4%25 mg vaginal matrix ring
NCT02858037 · Phase 3 · registry result, not featured evidence
0%
NCT03593655 · Phase 2 · registry result, not featured evidence
2.7%
NCT02028338 · Phase 2 · registry result, not featured evidence
1.4%
NCT02010593 · Phase 2 · registry result, not featured evidence
2.3%Dapivirine Gel 4759
NCT00799058 · Phase 1/2 · registry result, not featured evidence
0%Dapivirine Gel 4789
NCT00799058 · Phase 1/2 · registry result, not featured evidence
0%
NCT03239483 · Phase 1 · registry result, not featured evidence
3.1%
NCT01539226 · Phase na · registry result, not featured evidence
Most frequent reported AEs
25 mg DVR inserted once every 4 weeksa
metrorrhagia 55.1% (placebo 55.6%)
genitourinary chlamydia infection 20.5% (placebo 20.8%)
menorrhagia 19.7% (placebo 18.4%)
NCT01617096 · Phase 3 · monotherapy
show 9 more results
25 mg
infections 49.1%
reproductive system 20.9%
headache 3.5%
NCT02862171 · Phase 3
25 mg vaginal matrix ring
genitourinary chlamydia infection 8.4%
vaginal discharge 8%
vulvovaginitis trichomonal 5.9%
NCT02858037 · Phase 3 · registry result, not featured evidence
any event in soc 58.5%
any event in soc 32.4%
creatinine renal clearance decreased 30.3%
NCT03593655 · Phase 2 · registry result, not featured evidence
metrorrhagia 20.5% (placebo 26.1%)
vaginal discharge 15.1% (placebo 34.8%)
bacterial vaginosis 12.3% (placebo 8.7%)
NCT02028338 · Phase 2 · registry result, not featured evidence
vaginal discharge 11.1% (placebo 12.5%)
upper respiratory tract infection 8.3% (placebo 12.5%)
vaginal odour 6.9% (placebo 0%)
NCT02010593 · Phase 2 · registry result, not featured evidence
vaginitis bacterial 16.3% (placebo 11.9%)
vaginal candidiasis 9.3% (placebo 0%)
abdominal pain lower 4.7% (placebo 0%)
NCT00799058 · Phase 1/2 · registry result, not featured evidence
vaginitis bacterial 34.9% (placebo 11.9%)
vulvovaginal pruritus 9.3% (placebo 4.8%)
headache 7% (placebo 7.1%)
NCT00799058 · Phase 1/2 · registry result, not featured evidence
diarrhoea 11.1% (placebo 22.2%)
insomnia 11.1% (placebo 0%)
anal pruritus 5.6% (placebo 0%)
NCT03239483 · Phase 1 · registry result, not featured evidence
gynaecological chlamydia infection 32.7% (placebo 32.7%)
metrorrhagia 27% (placebo 29.6%)
genital infection female 23% (placebo 19.3%)
NCT01539226 · Phase na · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Dapivirine

HIV-1 Incidence Rate Per 100 PY 2.7 count @ 56.5wk25 mg vaginal matrix ring
event rate · count
No placebo or comparator arm
NCT02858037 · Phase 3 · registry result, not featured evidence
HIV-2 Seroconversion 0% (n=1302) vs 0% (n=650) placebo @ 104wk
event count · % of participants
NCT01539226 · Phase na · registry result, not featured evidence · converted to % from 0 Participants as posted

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dapivirine's landscape · Emtricitabine (Emtriva)'s landscape